Birr, C. et al. Pept., Proc. Eur. Pept. Symp., 16th (1981), Meeting Date 1980, 150-5. Editor(s): Brunfeldt, K. Publisher: Scriptor, Copenhagen, Den. C. |
Birr et al. Angew. Chem. (1979), 91(2), 156-7. |
Sandberg, Bengt E. B.; Ragnarsson, Ulf Solid phase synthesis of apamin, the principal neurotoxin in bee venom. Isolation and characterization of acetamidomethyl apamin Int. J. Pept. Protein Res. 11, 238-245, 1978. |
Schoeberl, Alfons; Rimpler, Manfred; Clauss, Eberhard. Structure of malformin. I. Syntheses of protected bisthiol peptides.Chem. Ber. (1970), 103(7), 2252-7. |
Deuel et al., "Amino acid sequence of human platelet factor 4", 1977, Proc. Natl. Acad. Sci. USA 74:2256-2258. |
Niedel and Cuatrecasas, 1980, "Formyl Peptide Chemotactic Receptors of Leukocytes and Macrophages", in Curr. Top. Cell. Reg. 17: 137-170. |
Deuel et al., "Platelet factor 4 is chemotactic for neutrophils and monocytes", 1981, Proc. Natl. Acad. Sci. USA 78:4584-4587. |
Zoghbi et al., "Selective cell labeling: A potential radioactive agent for labeling human neutrophils", 1981, J. Nucl. Med. 22: 32 (Abst). |
Jiang et al., "Localization of abscess with an iodinated synthetic chemotactic peptides", 1982, Nuklearmedizin 21:110-113. |
Osterman et al., "The carboxyl-terminal tridecapeptide of platelet factor 4 is a potent chemotactic agent for monocytes", 1982, Biochem. Biophys. Res. Comm. 107: 130-135. |
Holt & Niewiarowski, "Biochemistry of .alpha.-granule proteins", 1985, Sem. Hematol. 22: 151-163. |
Goldman et al., "Inhibition of human neutrophil receptor-mediated uptake of N-formyl-mey-leu-phe by platelet factor 4 (59-70)", 1985, Immunol. 54: 163-171. |
Loscalzo et al., "The interaction of platelet factor 4 and glycosaminoglycans", 1985, Arch. Biochem. Biophys. 240: 446-455. |
Bebawy et al., "In vitro effects of platelet factor 4 on normal human neutrophil functions", 1986. J. Leukocyte Biol. 39: 423-434. |
Wilkinson, "Chemotactic factors: An overview", 1988, Meth Enzymol. 162: 127-132. |
Vorne et al., "Technetium-99m HM-PAO-labeled leukocytes in detection of inflammatory lesions: Comparison with gallium-67 citrate", 1989, J. Nucl. Med. 30: 1332-1336. |
LaMuraglia et al., "Utility of the indium 111-labeled human immunoglobulin G scan for the detection of focal vascular graft infection", 1989, J. Vasc. Surg. 10: 20-28. |
Maione et al., "Inhibition of angiogenesis by recombinant human platelet factor 4 and related peptides", 1989, Science 247: 77-79. |
Lind et al., "Immunoscintigraphy of inflammatory processes with a technetium-99m-labeled monoclonal antigranulocyte antibody (MAb BW 250/183)", 1990, J. Nucl. Med. 31: 417-423. |
Fischman et al., "Imaging focal sites of bacterial infection in rats with indium-111-labeled chemotactic peptides analogs", 1991, J. Nucl. Med. 32: 483-491. |
Rhodes, 1974, "Considerations in the Radiolabeling of Albumin", Sem. Nucl. Med. 4: 281-293. |
Davidson et al., 1981, "A New Class of Oxotechnetium(5+) Chelate Complexes containing a TcON.sub.2 S.sub.2 Core", Inorg. Chem. 20: 1629-1632. |
Fritzberg et al., 1982, "Synthesis and Biological Evaluation of Tc-99m N,N'-Bis(mercaptoacetyl)-2,3-diaminopropanoate: A Potential Replacement for [.sup.131 I]o-iodohippurate", J. Nucl. Med. 23:592-598. |
Fritzberg et al., 1982, "Clinical comparison of Tc-99m N,N'-bis(mercaptoacetamido)ethylenediamine and (.sup.131 I) ortho-iodohippurate for evaluation of renal tubular function: Concise Communication", J. Nucl. Med. 23: P 17. |
Khaw et al., 1982, "Technetium-99m Labeling of Antibodies to Cardiac Myosin Fab and to Human Fibrinogen", J. Nucl. Med. 23: 1011-1019. |
Byrne and Tolman, 1983, "Technetium-99m Bifunctional Chelating Agent --Thiolactone for Coupling to Biomolecules, N.sub.2 S.sub.2 Ligand for Chelation to Technetium", J. Nucl. Med. 24: P126. |
Bryson et al., 1988, "Neutral Technetium(V) Complexes with Amide-Thiol-Thioether Chelating Ligands", Inorg. Chem. 27:2154-2161. |
Bryson et al., "Protection Groups in the Preparation of Thiolate Complexes of Technetium", Inorg. Chem. 29: 2948-2951. |
Knight et al., 1990, "Thrombus Imaging with Tc-99m Synthetic peptides Reactive with Activaed Platelets", J. Nucl. Med. 31: 757 #209. |
Deuel et al., 1977, Proc. Natl. Acad. Sci. USA 74: 2256-2258 disclose the amino acid sequence of human platelets factor 4. |
Niedel and Cuatrecasas, 1980, Formyl Peptide Chemotactic Receptors of Leukocytes and Macrophages in Curr. Top. Cell. Reg. 17: 137-170 disclose that formyl-methionyl-leucyl-phenylalanyl peptides causesuperoxide release from neutrophils. |
Deuel et al., 1981, Proc. Natl. Acad. Sci. USA 78: 4584-4587 disclose that platelet factor 4 ischemotactic for neutrophils and monocytes in vitro. |
Zoghbi et al., 1981, J. Nucl. Med. 22: 32 (Abst) disclose formyl peptide chemotactic factors (fMLF) derived from bacteria coupled to.sup.111 In-labeled transferrin. |
Jiang et al., 1982, Nuklearmedizin 21: 110-113 disclose a chemotactic formylated peptide (fMLF) radiolabeled with.sup.125 I. |
Osterman et al., 1982, Biochem. Biophys. Res. Comm. 107: 130-135 disclose that the carboxyl-terminaltridecapeptide of platelet factor 4 has chemotactic properties. |
Holt & Niewiarowski, 1985, Sem. Hematol. 22: 151-163 provide a review of the biochemistry of platelet .alpha.-granule proteis, including platelet factor 4. |
Goldman et al., 1985, Immunol. 54: 163-171 reveal that fMLF receptor-mediated uptake is inhibited in humanneutrophils by platelet factor 4 and a carboxyl-terminal dodecapeptide thereof. |
Loscalzo et al., 1985, Arch. Biochem. Biophys. 240: 446-455 describe the biochemical interaction between platelet factor 4 and glycosaminoglycans such as heparin. |
Bebawy et al., 1986, J. Leukocyte Biol. 39: 423-434 describe the platelet factor 4-mediatedchemotactic response of neutrophils in vitro. |
Wilkinson, 1988, Meth. Enzymol. 162: 127-132 discloses a method for characterizingchemotactic peptides capable of causing leukocytes to move up a peptide concentration gradient. |
Vorne et al., 1989, J. Nucl. Med. 30: 1332-1336 disclose the use of Tc-99m labeled leukocytes for imaging sites of infection. |
LaMuraglia et al., 1989, J. Vasc. Surg. 10: 20-28 disclose the use of.sup.111 In-labeled non-specific human immunoglobulin to detect sites of inflammation in vivo. |
Maione et al., 1989, Science 247: 77-79 disclose that angiogenesis is inhibited by recombinant human platelet factor 4 and peptide fragments thereof. |
Lind et al., 1990, J. Nucl. Med. 31: 417-473 disclose the use of Tc-99m labeled antigranulocyte monoclonal antibodies to detect inflammation. |
Fischman et al., 1991, J. Nucl. Med. 32: 482-491 relates to chemotactic formyl peptide (fMLF)-.sup.111 In-labeled DTPA conjugates. |
Hartman et al., 1992, "Non-peptide fibrinogen receptor antagonists: 1. Discovery and design ofexosite inhibitors", J. Med. Chem. 35: 4640-4642. |
Ojima et al., 1992, "Design and Synthesis of New RGD Peptides as Inhibitors of Human Platelet Aggregation", 204th Meeting, Amer. Chem. Soc. Abst. 44. |
Knight, 1990, "Radiopharmaceuticals for Thrombus Detection", Sem. Nucl. Med. 20: 52-67. |
Plow et al., 1987, in Perspectives in Inflammation, Neoplasia and Vascular Cell Biology, pp. 267-275. |